Drug intelligence / Profile preview

P44-L

Development stage: Preclinical
Lead developer: Minka Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

P44-L is a preclinical-stage chimeric antigen receptor (CAR) based cell therapy being developed by Minka Therapeutics for oncology indications. The program encompasses both CAR-T and CAR-NK cell modalities, designed to engineer immune cells to recognize and attack cancer cells. As of early 2026, the specific molecular targets remain undisclosed, and the therapy is undergoing validation in various oncology disease models.

Beyond the preview

Go deeper on P44-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P44-L.

Explore the full profile